Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Serum soluble interleukin-2 receptor (sIL-2R), intercellular adhesion molecule-1 (sICAM-1) and interleukin-10 (IL-10) have each been reported as useful markers for melanoma progression. To evaluate the clinical relevance of these three markers, we simultaneously analysed their serum levels in patients with melanoma. A longitudinal study with a 3-year follow-up was performed and different stages of the disease were considered. Mean values of sIL-2R were significantly higher than in normal controls in all stages and correlated with the disease progression. The prognosis of patients with levels > 529 U/ml of sIL-2R was significantly poorer than in patients with sIL-2R levels < 529 U/ml. Levels of sICAM-1 were also elevated in melanoma patients, specially at the time of the metastatic disease. Serum IL-10 levels were more frequently detectable in the patients that developed metastasis during follow-up, and the prognosis of patients with detectable IL-10 levels was significantly poorer than in those patients with IL-10 undetected levels. Statistical analysis based on Logistic and Cox regression models showed that only sex, stage and sIL-2R value are factors significantly associated with metastatic progression. Moreover, high levels of sIL-2R could be a risk factor for malignant progression in melanoma.
Boyano
M D
MD
Department of Cell Biology and Morphological Sciences, School of Medicine and Dentistry, University of the Basque Country, Leioa, Bizkaia, 48940, Spain.
Garcia-Vázquez
M D
MD
López-Michelena
T
T
Gardeazabal
J
J
Bilbao
J
J
Cañavate
M L
ML
Galdeano
A G
AG
Izu
R
R
Díaz-Ramón
L
L
Raton
J A
JA
Díaz-Pérez
J L
JL
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D016753:Interleukin-10 / Q000097:blood*; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000473:pathology / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012995:Solubility; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2; D018799:Intercellular Adhesion Molecule-1; D016753:Interleukin-10